Inactive Instrument

Other languages Novogen Limited Australian S.E.

Equities

Kazia Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 27
Kazia Therapeutics Limited Enters into an Exclusive Licensing Agreement Withsovargen Co., Ltd	Mar. 21
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study	Feb. 21
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint	Feb. 21
Kazia Therapeutics Limited Announces Appointment of Board Members	Jan. 18
Kazia Therapeutics Limited Announces Executive Changes	Jan. 12
Kazia Therapeutics Closes Sale of 4.4 Million American Depository Shares	Dec. 06
Kazia Therapeutics Launches $2 Million Registered Direct Offering; Shares Fall	Dec. 01
Kazia Therapeutics Signs Letter of Intent for Rights Licensing Deal	Nov. 29
Kazia Therapeutics Receives Nasdaq Deficiency Notice	Nov. 20
Kazia Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31

No results for this search